Workflow
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
ETONEton Pharmaceuticals(ETON) Newsfilter·2024-03-22 06:00

PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is expected to be accretive to 2024 earningsEstimated peak sales of more than 10millionannuallyU.S.phenylketonuria("PKU")medicalformulamarketestimatedtobe10 million annuallyU.S. phenylketonuria ("PKU") medical formula market estimated to be 100 million annually DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on deve ...